Open access
Open access
Powered by Google Translator Translator

Onco-hematology

Single-arm phase 1b study | Venetoclax Plus Gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia.

1 Aug, 2022 | 11:46h | UTC

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia – Journal of Clinical Oncology

 

Commentary on Twitter

 


RCT | Short vs. extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia.

27 Jul, 2022 | 12:17h | UTC

Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial – The Lancet Haematology (link to abstract – $ for full-text)

Commentary: Short-Course or Extended Antibiotics in Febrile Neutropenia? – Medscape (free registration required)

 

Commentary on Twitter

 


Cohort Study | Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors.

27 Jul, 2022 | 11:53h | UTC

Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors – Cancer

Commentaries:

People with early-stage Hodgkin lymphoma face a higher risk of dying from cardiovascular disease than from cancer – Wiley

CVD Mortality Leading Cause of Death for Stage I, II Hodgkin Lymphoma – HealthDay

 


RCT | Enasidenib vs. conventional care in mutant-IDH2 relapsed/refractory acute myeloid leukemia.

22 Jul, 2022 | 11:31h | UTC

Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial – Blood

 


The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends.

20 Jul, 2022 | 12:08h | UTC

The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends – The Lancet Haematology (free registration required)

 

Commentary on Twitter (thread – click for more)

 


Single-arm phase 2 study | Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma.

20 Jul, 2022 | 11:37h | UTC

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

 


ELN International Recommendations for the diagnosis and management of acute myeloid leukemia in adults.

19 Jul, 2022 | 13:28h | UTC

Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel – Blood

 


Single arm phase 2 study | Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for hematopoietic stem cell transplantation.

19 Jul, 2022 | 13:00h | UTC

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma – MedPage Today (free registration required)

Related:

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Zanubrutinib vs. bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

19 Jul, 2022 | 12:57h | UTC

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Zanubrutinib Wins in First-Line CLL for Older Patients — The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial – MedPage Today (free registration required)

 


RCT | Overall survival with Brentuximab Vedotin in stage III or IV Hodgkin’s lymphoma.

18 Jul, 2022 | 11:13h | UTC

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma – Mayo Clinic

 


The EBMT nursing guidelines on CAR-T Therapy | A framework for patient care and managing common toxicities.

14 Jul, 2022 | 12:45h | UTC

The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities – Clinical Hematology International

 


Review | Cardiovascular disease in myeloproliferative neoplasms.

14 Jul, 2022 | 12:38h | UTC

Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

 


Single-arm study | Long-term benefits of Tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm.

14 Jul, 2022 | 12:13h | UTC

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm – Journal of Clinical Oncology

Related Study: Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm – New England Journal of Medicine

 


RCT | Neutropenic versus regular diet for acute leukemia induction chemotherapy.

13 Jul, 2022 | 11:45h | UTC

Neutropenic versus regular diet for acute leukaemia induction chemotherapy: randomised controlled trial – BMJ Supportive & Palliative Care (link to abstract – $ for full-text)

Related:

Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline – Journal of Clinical Oncology

Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer – European Journal of Cancer (link to abstract – $ for full-text)

Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis – BMJ Supportive & Palliative Care (link to abstract – $ for full-text)

Things We Do For No Reason: Neutropenic Diet – Journal of Hospital Medicine (PDF)

 


RCT | Zanubrutinib vs. bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

11 Jul, 2022 | 11:49h | UTC

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 


Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy.

8 Jul, 2022 | 11:53h | UTC

Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia – Clinical Cardiology

Related:

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis – European Heart Journal

Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis – 2021 – Arquivos Brasileiros de Cardiologia

AHA Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis.

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases – European Heart Journal

Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association – Circulation

Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis – Canadian Journal of Cardiology

AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management – JACC: CardioOncology

Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis – Circulation: Heart Failure

 


RCT | Efficacy and safety of a Pegasparaginase-based chemotherapy regimen vs. an L-asparaginase–based chemotherapy regimen for newly diagnosed advanced extranodal Natural Killer/T-Cell Lymphoma.

8 Jul, 2022 | 11:21h | UTC

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)

Editorial: De-escalating Chemotherapy for Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Step Toward Improved Treatment of a Rare Virus-Associated Cancer – JAMA Oncology (free for a limited period)

See also: Visual Abstract

 


Cohort Study | Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma.

5 Jul, 2022 | 11:39h | UTC

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts – Journal of Clinical Oncology

News Release: Mantle cell lymphoma treatment varies according to setting – Weill Cornell Medicine


RCT | CT vs. [18F]FDG-PET-CT for persistent or recurrent neutropenic fever in high-risk patients.

4 Jul, 2022 | 12:21h | UTC

[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)

 

Commentary on Twitter


FDA warns about possible increased risk of death and serious side effects with duvelisib.

4 Jul, 2022 | 11:51h | UTC

FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib – The ASCO Post


2022 Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.

1 Jul, 2022 | 11:50h | UTC

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 – The Lancet Oncology

Related:

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy – Cochrane Library

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer – Blood Advances

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review

 


Editorial | Circulating tumor cell burden as a component of staging in multiple myeloma: ready for prime time?

4 Jul, 2022 | 11:48h | UTC

Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time? – Journal of Clinical Oncology

Original Studies:

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma – Journal of Clinical Oncology

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma – Journal of Clinical Oncology

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile – Journal of Clinical Oncology


Single-arm phase II study: Venetoclax added to Cladribine plus low-dose Cytarabine alternating with 5-Azacitidine in older patients with newly diagnosed acute myeloid leukemia.

30 Jun, 2022 | 10:14h | UTC

Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


Cohort Study: Burden of long-term morbidity borne by survivors of acute myeloid leukemia treated with blood or marrow transplantation.

29 Jun, 2022 | 10:56h | UTC

Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study – Journal of Clinical Oncology

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by-nc-nd/4.0/ license

 


Brief Review | Never above suspicion: getting to the bottom of cardiac sarcoidosis diagnosis and treatment.

29 Jun, 2022 | 10:50h | UTC

Never Above Suspicion: Getting to the Bottom of Cardiac Sarcoidosis Diagnosis and Treatment – American College of Cardiology

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.